Phase 2 Leukaemia Trial, Recruiting (NCT07108530)

Phase 2 Leukaemia Trial, Recruiting NCT07108530 Sponsor: Shanxi Bethune Hospital Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT07108530 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 14 and 65 years old
You have been diagnosed with Acute Myeloid Leukemia (AML), but not the specific type called AML-M3 (also known as Acute Promyelocytic Leukemia)
Your diagnosis matches a specific set of Chinese medical guidelines for AML from 2023, and your condition may be low, intermediate, or high risk
Your bone marrow test shows either an unusually high or unusually low number of cells (confirm with trial site)
You are generally able to carry out daily activities, or have only mild limitations due to your illness (based on a standard medical scoring system)

Who may not be able to join:

You have bleeding in the brain (intracranial hemorrhage)
You are pregnant
You have a mental health condition or other issue that might make it difficult to follow the trial's instructions and schedule
You have a serious irregular heartbeat, or a specific abnormality shown on a heart tracing test (ECG) where a measurement called QTc is greater than 500 ms (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13835175119

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07108530

Sponsor: Shanxi Bethune Hospital

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

Trial contact: 13835175119

More information: https://clinicaltrials.gov/study/NCT07108530

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 14 and 65 years old
You have been diagnosed with Acute Myeloid Leukemia (AML), but not the specific type called AML-M3 (also known as Acute Promyelocytic Leukemia)
Your diagnosis matches a specific set of Chinese medical guidelines for AML from 2023, and your condition may be low, intermediate, or high risk
Your bone marrow test shows either an unusually high or unusually low number of cells (confirm with trial site)
You are generally able to carry out daily activities, or have only mild limitations due to your illness (based on a standard medical scoring system)

Who may not be able to join:

You have bleeding in the brain (intracranial hemorrhage)
You are pregnant
You have a mental health condition or other issue that might make it difficult to follow the trial's instructions and schedule
You have a serious irregular heartbeat, or a specific abnormality shown on a heart tracing test (ECG) where a measurement called QTc is greater than 500 ms (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Shanxi Bethune Hospital

Registry

ClinicalTrials.gov

Start date

6 August 2025

Est. completion

6 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease-Free Survival (DFS); The Complete Response (CR) rate; Partial Response (PR) rate; No Remission (NR); CR with incomplete hematologic recovery (CRi); Therapeutic efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov